Effect of age on survival in patients undergoing resection of hepatocellular carcinoma

British Journal of Surgery

Volumn 103, Issue 2, 2016, Pages e93-e99

  Cucchetti, A ^a   Sposito, C ^b   Pinna, A D ^a   Citterio, D ^b   Ercolani, G ^a   Flores, M ^b   Cescon, M ^a   Mazzaferro, V ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84954523681     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.10056     Document Type: Article

References (26)

1. US Department of Health and Human Services. Global Health and Aging. http://www.nia.nih.gov/research/publication/global-health-and-aging/preface [accessed 1 July 2015].
2. El-Serag HB,. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
3. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al,. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
5. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
6. Borzio M, Dionigi E, Parisi G, Raguzzi I, Sacco R,. Management of hepatocellular carcinoma in the elderly. World J Hepatol 2015; 7: 1521-1529.
7. Nishikawa H, Kimura T, Kita R, Osaki Y,. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013; 4: 635-643.
8. Le Teuff G, Abrahamowicz M, Bolard P, Quantin C,. Comparison of Cox's and relative survival models when estimating the effects of prognostic factors on disease-specific mortality: a simulation study under proportional excess hazards. Stat Med 2005; 24: 3887-3909.
9. Hakulinen T, Tenkanen L,. Regression analysis of relative survival rates. Appl Statist 1987; 36: 309-317.
10. National Cancer Institute. Statistical Methodology and Applications Branch, Data Modeling Branch. http://surveillance.cancer.gov/cansurv/index.html [accessed 1 July 2015].
11. Gardner JW, Sanborn JS,. Years of potential life lost (YPLL)-what does it measure? Epidemiology 1990; 1: 322-329.
12. Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, et al,. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012; 256: 706-712.
13. Strasberg SM, Belghiti J, Clavien PA, Gadzijev E, Garden JO, Lau WY, et al., The Brisbane 2000 terminology of liver anatomy and resections. Terminology Committee of the International Hepato-Pancreato-Biliary Association. HPB 2000; 2: 333-339.
14. Cucchetti A, Zanello M, Cescon M, Ercolani G, Del Gaudio M, Ravaioli M, et al,. Improved diagnostic imaging and interventional therapies prolong survival after resection for hepatocellular carcinoma in cirrhosis: the University of Bologna experience over 10 years. Ann Surg Oncol 2011; 18: 1630-1607.
15. Chu PC, Wang JD, Hwang JS, Chang YY,. Estimation of life expectancy and the expected years of life lost in patients with major cancers: extrapolation of survival curves under high-censored rates. Value Health 2008; 11: 1102-1109.
16. Hwang JS, Wang JD,. Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. Stat Med 1999; 18: 1627-1640.
17. Wang J-D,. Study design. In Basic Principles and Practical Applications in Epidemiological Research. World Scientific: Singapore, 2002; 161-196.
18. Istat. Italian Population Life Tables. http://demo.istat.it [accessed 1 June 2015].
19. Liu PH, Wang JD, Keating NL,. Expected years of life lost for six potentially preventable cancers in the United States. Prev Med 2013; 56: 309-313.
20. Cucchetti A, Djulbegovic B, Tsalatsanis A, Vitale A, Hozo I, Piscaglia F, et al,. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology 2015; 61: 905-914.
21. Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, et al,. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 2015; 62: 440-451.
22. Cucchetti A, Ross FL, Thistlethwaite JR Jr, Vitale A, Ravaioli M, Cescon M, et al,. Age and equity in liver transplant: an organ allocation model. Liver Transpl 2015; 21: 1241-1249.
23. Daniels N., The prudential lifespan account of justice across generations. In Justice and Justification. Cambridge University Press: Cambridge, 1996; 257-283.
24. Margarit C, Escartín A, Castells L, Vargas V, Allende E, Bilbao I,. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 2005; 11: 1242-1251.
25. Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J,. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 2012; 55: 132-140.
26. Cucchetti A, Cescon M, Trevisani F, Morelli MC, Ercolani G, Pellegrini S, et al,. What is the probability of being too old for salvage transplantation after hepatocellular carcinoma resection? Dig Liver Dis 2012; 44: 523-529.